HOME >> BIOLOGY >> NEWS
Researchers discover new mechanism that targets and destroys abnormal RNA

c diseases in which mutations cause premature termination of protein production.

A specific example is the testing of drugs called aminoglycosides to treat cystic fibrosis and other diseases caused by premature termination codons, said Dietz. The idea is that these drugs would allow read-through of such codons, to generate adequate levels of full-length functional proteins. Unfortunately, these drugs have not performed very well, he said.

Our studies of the effects of one such drug on yeast indicate that this read-through generates mRNAs that trigger the nonstop decay mechanism to degrade them, said Dietz. This finding offers the promise that drugs that inhibit nonstop decay might enable aminoglycoside drugs to function as effective treatments for some genetic diseases.

Termination codons are present in about one-third of human disease genes, representing literally thousands of genes, said Dietz. So this dual-drug treatment strategy could be relevant to a large number of human disorders, including cystic fibrosis and muscular dystrophy.

In the second Science paper, lead author Ambro van Hoof, in Parkers laboratory, did experiments that revealed the specific cellular machinery that produces nonstop decay. According to Parker, those experiments showed that a multi-enzyme complex called the exosome is important for nonstop decay.

The exosome is a collection of enzymes called exonucleases that snip apart RNA molecules. In their experiments, van Hoof, Parker and their colleagues set out to see if the exosome was involved in nonstop mRNA decay.

It was known that the exosome was involved in a variety of RNA degradation processes in the cell, probably controlled through specific adapters, although we really dont understand the mechanisms well, said Parker. According to Parker, the adapter protein, which is attached to the exosome, somehow recognizes the nonstop RNA and attaches to the ribosome.

Parker, van Hoof
'"/>

Contact: Jim Keeley
keeleyj@hhmi.org
301-215-8858
Howard Hughes Medical Institute
21-Mar-2002


Page: 1 2 3 4

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... 2015   Marvin Test Solutions , ... test solutions for military, aerospace, and manufacturing ... TS-323 GENASYS Test Platform to ... is a high-performance PXI-based system designed to ... require performance functional testing. GENASYS features a ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4
(Date:2/28/2015)... 2015 Increasing its efforts to resolve the ... first three episodes of The GMO TRUTH podcast on both ... as it continues its mission to discover the truth and ... phase, to “uncover the truth about the GMOs in our ... GMO Truth Podcast is an expansion of the documentary/investigative film-making ...
(Date:2/27/2015)... Calif. , Feb. 27, 2015  Pharmacyclics, ... that longer-term toxicology studies for its newly developed ... or RA, have been completed. The results of ... U.S. Food and Drug Administration. The feedback received ... of the ongoing first-in-human study. Additional preclinical work ...
(Date:2/27/2015)... Halifax, Nova Scotia (PRWEB) February 27, 2015 ... clinical stage vaccine and immunotherapy company, today announced ... approved its application for Fast Track designation and ... DPX-Ebola vaccines, in conjunction with the mutual co-development ... had previously obtained Fast Track designation for the ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE ... development of biosimilar therapeutics, today announced that it will ... Marriott Marquis on March 2 nd at 3pm ... on a panel discussing the current state of the ... Biosimilars . For more information on ...
Breaking Biology Technology:The Walk a Mile Project Launches “GMO Truth” Podcast 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
Cached News: